Stephens & Co. Reiterates Overweight on Evolent Health, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jeff Garro has reiterated an Overweight rating on Evolent Health (NYSE:EVH) and maintained a price target of $42.
July 30, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. analyst Jeff Garro has reiterated an Overweight rating on Evolent Health (NYSE:EVH) and maintained a price target of $42.
The reiteration of an Overweight rating and a maintained price target of $42 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100